pertussis
Vaccines · 2011–2015
No submission for this condition has carried consumer input, including the 2 made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| pertussis vaccine-acellular, combined with diphtheria and tetanus toxoids (DTaP) Prevention of pertussis as an 18-month booster dose in infants aged approximately 18 months. | Jul 2015 | Recommended with restriction | none received |
| diphtheria + tetanus + acellular pertussis vaccine Prevention of pertussis as an 18-month booster dose in the National Immunisation Program schedule. | Nov 2014 | Recommended | none received |
| Pertussis vaccine-acellular combined with diphtheria and tetanus toxoids (Adsorbed) Single dose booster immunisation against tetanus, diphtheria and pertussis to both parents of newborn infants where there is no documented evidence of a dTpa… | Nov 2011 | Not recommended | no section in document |
What the PBS pays
$10M in government benefit over 2024–25, across 76,970 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| Pertussis vaccine-acellular, combined with diphtheria and tetanus toxoids (DTaP) | $5M |
| diphtheria + tetanus + acellular pertussis vaccine | $5M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.